Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ho

Showing results (1211-1220 of 1,367) with videos related to

Pageof 137
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Schetelig, C Thiede, M Bornhauser, et al.
Emerging Microbes & Infections|November 10, 2022
Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2Mengxiao Luo, Biao Zhou, Eswar R Reddem, et al.
Bone Marrow Transplantation|July 7, 2015
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapseM Hahn, S Böttcher, S Dietrich, et al.
Emerging Microbes & Infections|September 15, 2020
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe diseasePengfei Wang, Lihong Liu, Manoj S Nair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Nature Medicine|July 1, 1996
Ordered accumulation of mutations in HIV protease confers resistance to ritonavirA Molla, M Korneyeva, Q Gao, et al.
Cell Host & Microbe|April 22, 2020
VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgAManxue Jia, Rachel A Liberatore, Yicheng Guo, et al.
European Journal of Pharmacology|May 7, 2011
The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent speciesSherry X Lu, Guy A Higgins, Robert A Hodgson, et al.
Nature Cell Biology|March 21, 2017
Human haematopoietic stem cell lineage commitment is a continuous processLars Velten, Simon F Haas, Simon Raffel, et al.
Cancer Investigation|September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaUlrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Pageof 137

Showing results (1211-1220 of 1,367) with videos related to

Sort By:
Pageof 137
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Schetelig, C Thiede, M Bornhauser, et al.
Emerging Microbes & Infections|November 10, 2022
Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2Mengxiao Luo, Biao Zhou, Eswar R Reddem, et al.
Bone Marrow Transplantation|July 7, 2015
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapseM Hahn, S Böttcher, S Dietrich, et al.
Emerging Microbes & Infections|September 15, 2020
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe diseasePengfei Wang, Lihong Liu, Manoj S Nair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Nature Medicine|July 1, 1996
Ordered accumulation of mutations in HIV protease confers resistance to ritonavirA Molla, M Korneyeva, Q Gao, et al.
Cell Host & Microbe|April 22, 2020
VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgAManxue Jia, Rachel A Liberatore, Yicheng Guo, et al.
European Journal of Pharmacology|May 7, 2011
The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent speciesSherry X Lu, Guy A Higgins, Robert A Hodgson, et al.
Nature Cell Biology|March 21, 2017
Human haematopoietic stem cell lineage commitment is a continuous processLars Velten, Simon F Haas, Simon Raffel, et al.
Cancer Investigation|September 20, 2006
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphomaUlrich J M Mey, Katjana S Orlopp, Dimitri Flieger, et al.
Pageof 137